Bristol-Myers Squibb Company (BMY) on Decifer

Decifer ranks BMY number 138 of 265 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 15% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is not growing right now and profits grew 178% over the past year.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• 15 percent returns and 178 percent profit growth are fine quality but flat revenue, 10 momentum, and no funded role leave growth conviction low.

The current read

The evidence on BMY lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full BMY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.